Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474427 | 0.91 | P2RX7 (0.54) | P2RX7ABCB11 | |
| SCHEMBL3474832 | 0.90 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL3473746 | 0.90 | P2RX7 (0.53) | P2RX7ALDH1A1 | |
| SCHEMBL3476061 | 0.88 | P2RX7 (0.53) | P2RX7MAPK14ABCB11 | |
| SCHEMBL3475802 | 0.88 | P2RX7 (0.53) | P2RX7MAPK14ABCB11 | |
| SCHEMBL3474454 | 0.88 | P2RX7 (0.53) | P2RX7MAPK14ABCB11 | |
| SCHEMBL3475129 | 0.88 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL5957132 | 0.87 | P2RX7 (0.46) | P2RX7HTTMITFALDH1A1LMNA | |
| SCHEMBL3476206 | 0.85 | P2RX7 (0.49) | P2RX7SMN1; SMN2 | |
| SCHEMBL3474584 | 0.85 | P2RX7 (0.49) | P2RX7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671053-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090042886-A1 | Benzamide Inhibitors of the P2X7 Receptor | PFIZER, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-7407956-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070281939-A1 | Benzamide Inhibitors of The P2X7 Receptor | PFIZER INC. | 2007-12-06 | — | — | US | disclosed |
| US-7176202-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060040939-A1 | Benzamide inhibitors of the P2X, receptor | DOMBROSKI MARK A | 2006-02-23 | — | — | US | disclosed |
| US-20060018904-A1 | Combination therapies utilizing benzamide inhibitors of the P2X7 receptor | WARNER-LAMBERT COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-6974812-B2 | Benzamide inhibitors of the P2X7 Ereceptor | PFIZER INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1581232-A1 | 3-(3,5-DIOXO-4,5-DIHYDRO-3H-(1,2,4)TRIAZIN-2-YL)-BENZAMIDE DERIVATIVES AS P2X7-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180894-A1 | such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis) | PFIZER INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004058270-A1 | 3-(3,5-DIOXO-4,5-DIHYDRO-3H-(1,2,4)TRIAZIN-2-YL)-BENZAMIDE DERIVATIVES AS P2X7-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042886-A1 | Benzamide Inhibitors of the P2X7 Receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885HTT 3255/4885MITF 3238/4885 |
| US-20040180894-A1 | such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis) | IL1R1, P2RY1, P2RX7 | P2RX7 3/4885HTT 1728/4885MITF 3237/4885 |
| US-20060018904-A1 | Combination therapies utilizing benzamide inhibitors of the P2X7 receptor | CSF3R, CSF1R, IL1R1 | P2RX7 72/4885HTT 4109/4885MITF 3041/4885 |
| US-20070281939-A1 | Benzamide Inhibitors of The P2X7 Receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885HTT 3255/4885MITF 3238/4885 |
| US-20060040939-A1 | Benzamide inhibitors of the P2X, receptor | IL1R1, P2RX1, P2RX3 | P2RX7 7/4885HTT 3315/4885MITF 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.